TP53 and lung adenocarcinoma: The top three combinations were TP53 mutations in lung adenocarcinoma (LUAD; modulating response to 235 drugs), lung squamous cell carcinoma (LUSC; 228 drugs), and stomach adenocarcinoma (STAD; 224 drugs) (Table 2).